The U.S. Food and Drug Administration on Tuesday approved Ajovy, an injection made by Israeli drugmaker Teva Pharma , to help ...

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) reported its second-quarter 2025 financial results on Wednesday, reflecting a mixed performance amid continued shifts in its portfolio strategy. The ...

Teva raised 2025 guidance for Austedo, Ajovy, and Uzedy after Q2 earnings beat estimates, despite missing revenue expectations.

👑 📉 Magnificent 7 no more? Why US tech is no longer moving as one unstoppable pack. Ask WarrenAI Teva Pharma shares rise 3% as Q2 earnings beat expectations Earnings Published 07/30/2025, 07 ...

Teva Pharmaceutical Industries reported a better than expected increase in second-quarter profit on Wednesday, helped by a 26% rise in sales of its branded drugs and said it was well positioned to ...

NEW YORK - On Wednesday, Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) reported second-quarter earnings that exceeded analyst expectations, as the company continues to execute its "Pivot to Growth" ...

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) saw its shares rise 3.08% in pre-market trading on Wednesday following better-than-expected second-quarter earnings, reflecting progress in its ...

Teva Pharmaceutical Industries Limited (NYSE: TEVA) is one of the best strong buy healthcare stocks to buy now. In a report released on July 21, Sabina Levi from Leader Capital Markets maintained ...

Alcohol Use Disorder Pipeline 2025: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Alkermes, Teva Pharma, BioCorRx, Inc., Adial Pharma, ADDEX THER ...

Key companies developing therapies for Alcohol Use Disorder are - Alkermes, Teva Pharmaceutical Industries Ltd., BioCorRx, Inc., Adial Pharmaceuticals, ADDEX THERAPEUTICS, Kinnov Therapeutics ...